China Sees Explosion Of R&D Outsourcing Business In Three Years
This article was originally published in PharmAsia News
Executive Summary
In the three years since China began offering drug discovery and development services to foreign drug makers, the industry has become a world leader offering a wide range of services. The contract research industry in China was built in part by attracting skilled scientists and managers from Japan, the United States and other countries. A similar industry is expanding in India. China and India are taking advantage of a perceived need by Western drug makers to trim the average $1 billion cost of bringing new drugs to market. (Click here for more
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.